Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · IEX Real-Time Price · USD
154.20
-2.55 (-1.63%)
At close: Jul 2, 2024, 4:00 PM
156.00
+1.80 (1.17%)
After-hours: Jul 2, 2024, 4:57 PM EDT
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $1.40B in the twelve months ending March 31, 2024, with 43.83% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $413.46M with 63.10% year-over-year growth. In the year 2023, Sarepta Therapeutics had annual revenue of $1.24B with 33.26% growth.
Revenue (ttm)
$1.40B
Revenue Growth
+43.83%
P/S Ratio
10.39
Revenue / Employee
$1,067,960
Employees
1,314
Market Cap
14.58B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
Dec 31, 2019 | 380.83M | 79.80M | 26.51% |
Dec 31, 2018 | 301.03M | 146.45M | 94.74% |
Dec 31, 2017 | 154.58M | 149.16M | 2,751.58% |
Dec 31, 2016 | 5.42M | 4.17M | 332.64% |
Dec 31, 2015 | 1.25M | -8.50M | -87.16% |
Dec 31, 2014 | 9.76M | -4.46M | -31.38% |
Dec 31, 2013 | 14.22M | -23.11M | -61.91% |
Dec 31, 2012 | 37.33M | -9.66M | -20.56% |
Dec 31, 2011 | 46.99M | 17.57M | 59.72% |
Dec 31, 2010 | 29.42M | 11.84M | 67.30% |
Dec 31, 2009 | 17.59M | -3.67M | -17.28% |
Dec 31, 2008 | 21.26M | 10.27M | 93.52% |
Dec 31, 2007 | 10.99M | 10.87M | 9,428.06% |
Dec 31, 2006 | 115.29K | -4.67M | -97.59% |
Dec 31, 2005 | 4.78M | 4.35M | 1,011.31% |
Dec 31, 2004 | 430.46K | -539.41K | -55.62% |
Dec 31, 2003 | 969.87K | 133.08K | 15.90% |
Dec 31, 2002 | 836.78K | 130.68K | 18.51% |
Dec 31, 2001 | 706.10K | -591.24K | -45.57% |
Dec 31, 2000 | 1.30M | 1.28M | 7,520.64% |
Dec 31, 1999 | 17.02K | -103.33K | -85.85% |
Dec 31, 1998 | 120.35K | 106.01K | 738.98% |
Dec 31, 1997 | 14.35K | -12.88K | -47.31% |
Dec 31, 1996 | 27.23K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Quest Diagnostics | 9.29B |
Incyte | 3.77B |
Waters | 2.91B |
BeiGene | 2.76B |
Genmab | 2.57B |
United Therapeutics | 2.50B |
BioMarin Pharmaceutical | 2.47B |
Neurocrine Biosciences | 1.98B |
SRPT News
- 4 days ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 days ago - Will Elevidys Approval Make Sarepta Stock An Acquisition Target? - Forbes
- 11 days ago - Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty - Benzinga
- 11 days ago - Wall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label Approval - Business Wire
- 11 days ago - Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says - Benzinga
- 11 days ago - Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug - Investopedia
- 11 days ago - Sarepta Therapeutics' stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug - Market Watch
- 11 days ago - Sarepta Stock Surges on Expanded Approval for Elevidys. What Wall Street Thinks. - Barrons